Telix Pharmaceuticals Limited (TLX) fair value: what the stock is really worth
We calculate from audited financials what Telix Pharmaceuticals Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value $0.2800 · Strongly overvalued (−98%)
!Quality 40/100
!Mixed Growth(revenue 5y +197.0 %/yr)
!Loss-making · -0.9% net margin (TTM)
!Moderate debt · negative free cash flow
!Mixed vs. peers(4/10)
!Narrow moat20/100
!Evidence only low, so the estimate is less certain
Watch Telix Pharmaceuticals Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 19, 2026.
How to read this chart
22‑month range $6.41 – $20.93 · fair‑value band $0.1600 – $0.3800 · the $11.31 price screens above the $0.2800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 19, 2026.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Show more
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Stock analysis
Telix Pharmaceuticals Limited (TLX) currently trades at $11.31, while our model-based Fair Value estimate is $0.2800, implying the stock looks roughly 3,932.3% overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of $2.45 per share, and 0 of the 8 models we run sit above the $11.31 price.
Bear case: the Earnings-Based group reads lowest at $0.2100, and 8 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1600 (bear) to $0.3800 (bull), the price of $11.31 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Telix Pharmaceuticals Limited reported revenue of $1.2B in FY2025 versus $7.6M in FY2021, a compound +254.9%/yr. Reported net income was −$10.7M in FY2025.
Key figures
Market cap $3.8B · P/S ratio 4.53 · EPS (TTM) $−0.0200 · Dividend yield 1.5% · Net margin −0.9% · Return on equity −1.9% · Return on assets (EBIT) −19.8% · Operating margin 1.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 80% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −98%, TLX screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.2100 to $2.83). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $0.1600Fair Value $0.2800Bull $0.3800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+53.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+96.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+197.0%
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.5%
’13
’14
’15
’16
’17
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−847.7% (2020) → 2.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (82 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Telix Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−92% · Bottom 25%
Profitability
Return on assets1% · Above median
Net margin (TTM)−1% · Below median
Operating margin (TTM)2% · Above median
Growth and dividend
Revenue growth49% · Top 25%
Dividend yield (TTM)1.5% · Above median
Balance sheet
Debt / equity0.63× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.85× · Priciest 25%
P/S (TTM)4.53× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)69· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Telix Pharmaceuticals Limited (TLX) overvalued or undervalued?
As of Sep 19, 2026, our model estimates a fair value of $0.2800 versus a price of $11.31, about −98% upside (overvalued).
What is the fair value of TLX?
Our model-based fair value for Telix Pharmaceuticals Limited is $0.2800 (as of Sep 19, 2026), built from audited fundamentals. The current price: $11.31.
What is the quality score of TLX?
Telix Pharmaceuticals Limited has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Telix Pharmaceuticals Limited (TLX)?
Our model-based price target is the fair value of $0.2800 (as of Sep 19, 2026) from 8 valuation models. Cautious scenario $0.1600, optimistic scenario $0.3800. It is a calculation from audited fundamentals, not an analyst target.
What is the Telix Pharmaceuticals Limited stock forecast for 2026?
Our models put fair value at $0.2800, about −98% upside versus a price of $11.31 (overvalued). Cautious scenario $0.1600, optimistic scenario $0.3800. The calculation is refreshed regularly with new filings.
What is the revenue of Telix Pharmaceuticals Limited (TLX)?
Telix Pharmaceuticals Limited reported trailing-twelve-month revenue of about $804M (latest available figure, as of Sep 19, 2026).
Does Telix Pharmaceuticals Limited pay a dividend?
Telix Pharmaceuticals Limited currently shows a dividend yield of about 1.51% relative to its recent price (as of Sep 19, 2026).
What is the intrinsic value of Telix Pharmaceuticals Limited (TLX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Telix Pharmaceuticals Limited it is $0.2800 per share (as of Sep 19, 2026), against a price of $11.31. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Telix Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Sep 19, 2026, TLX trades above its calculated fair value: price $11.31, fair value $0.2800, a gap of about −98% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TLX?
No. The price is what the market pays today ($11.31); the fair value is what the company's own numbers justify ($0.2800). For Telix Pharmaceuticals Limited the two are $11.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Telix Pharmaceuticals Limited worth?
The market values Telix Pharmaceuticals Limited at about $3.8B (market capitalisation, as of Sep 19, 2026). Per share that is $11.31; our models calculate a fair value of $0.2800 per share.
What do the bullish and bearish scenarios say about TLX?
Our models span a range for Telix Pharmaceuticals Limited: cautious scenario $0.1600, base $0.2800, optimistic $0.3800 per share (as of Sep 19, 2026, price $11.31). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Telix Pharmaceuticals Limited (TLX)?
Balance-sheet figures for Telix Pharmaceuticals Limited (as of Sep 19, 2026): return on equity −1.9%, debt of 0.63 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is TLX from its 52-week high?
Telix Pharmaceuticals Limited trades at $11.31, about 33% below its 52-week high of $16.98 and 80% above the low of $6.28 (as of Sep 19, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2800 is for.
Which stocks are comparable to Telix Pharmaceuticals Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Telix Pharmaceuticals Limited stock attractive at the current price?
The data as of Sep 19, 2026: price $11.31, calculated fair value $0.2800 (−98%), Quality Score 40/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TLX calculated?
We run Telix Pharmaceuticals Limited through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Telix Pharmaceuticals Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Telix Pharmaceuticals Limited (TLX)?
The closing price on Sep 21, 2026 was $11.31. Our model-based fair value is $0.2800, about −98% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Telix Pharmaceuticals Limited right now?
The price sits above even our optimistic bull case ($0.3800). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1600 to $0.3800) leaves room in how you read the outcome.
Key figures of Telix Pharmaceuticals Limited
How large is the market capitalisation of Telix Pharmaceuticals Limited (TLX)?
The market capitalisation of Telix Pharmaceuticals Limited is $3.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Telix Pharmaceuticals Limited (TLX)?
The price-to-sales ratio of Telix Pharmaceuticals Limited is 4.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Telix Pharmaceuticals Limited (TLX)?
Earnings per share at Telix Pharmaceuticals Limited are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Telix Pharmaceuticals Limited (TLX)?
The dividend yield of Telix Pharmaceuticals Limited is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Telix Pharmaceuticals Limited (TLX)?
The net margin of Telix Pharmaceuticals Limited is −0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Telix Pharmaceuticals Limited (TLX)?
The return on equity (ROE) of Telix Pharmaceuticals Limited is −1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Telix Pharmaceuticals Limited (TLX)?
On an EBIT basis the return on assets of Telix Pharmaceuticals Limited is −19.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Telix Pharmaceuticals Limited (TLX)?
The operating margin of Telix Pharmaceuticals Limited is 1.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Telix Pharmaceuticals Limited (TLX)?
Revenue at Telix Pharmaceuticals Limited is growing +49.3% versus a year earlier (3y avg +96.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Telix Pharmaceuticals Limited (TLX) generate?
The free cash flow of Telix Pharmaceuticals Limited is −$82.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Telix Pharmaceuticals Limited (TLX) carry?
The net debt of Telix Pharmaceuticals Limited is $487M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Telix Pharmaceuticals Limited in the live analysis
One click puts Telix Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 19, 2026